TherapeuticsMD, Inc. (NASDAQ:TXMD) was the recipient of a large growth in short interest during the month of October. As of October 13th, there was short interest totalling 41,131,584 shares, a growth of Infinity from the September 29th total of 0 shares. Based on an average daily volume of 3,688,148 shares, the short-interest ratio is currently 11.2 days. Currently, 23.7% of the shares of the stock are sold short.

In related news, Director Tommy G. Thompson bought 5,000 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was bought at an average cost of $5.99 per share, with a total value of $29,950.00. Following the completion of the purchase, the director now owns 3,555 shares in the company, valued at approximately $21,294.45. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 23.92% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Managed Account Services Inc. raised its holdings in TherapeuticsMD by 5.5% in the 2nd quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock valued at $101,000 after buying an additional 1,000 shares during the last quarter. Amalgamated Bank raised its holdings in TherapeuticsMD by 7.2% in the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after buying an additional 1,322 shares during the last quarter. Principal Financial Group Inc. raised its holdings in TherapeuticsMD by 3.9% in the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after buying an additional 818 shares during the last quarter. Traynor Capital Management Inc. raised its holdings in TherapeuticsMD by 14.0% in the 2nd quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock valued at $123,000 after buying an additional 2,799 shares during the last quarter. Finally, Virtu KCG Holdings LLC bought a new position in TherapeuticsMD in the 2nd quarter valued at approximately $157,000. Institutional investors and hedge funds own 71.55% of the company’s stock.

A number of equities analysts have weighed in on TXMD shares. Oppenheimer Holdings, Inc. raised shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Tuesday, July 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $33.00 target price on shares of TherapeuticsMD in a research note on Friday, July 21st. CIBC raised shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. Noble Financial reaffirmed a “buy” rating on shares of TherapeuticsMD in a research note on Friday, August 4th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $15.00 target price on shares of TherapeuticsMD in a research note on Friday, September 8th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $14.88.

TherapeuticsMD (TXMD) opened at 5.00 on Wednesday. The firm has a 50 day moving average of $4.89 and a 200-day moving average of $4.89. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30. The company’s market capitalization is $1.02 billion.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Thursday, August 3rd. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $4.25 million during the quarter, compared to analysts’ expectations of $4.91 million. TherapeuticsMD had a negative net margin of 485.71% and a negative return on equity of 74.25%. The business’s revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.11) earnings per share. On average, analysts forecast that TherapeuticsMD will post ($0.44) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Short Interest in TherapeuticsMD, Inc. (TXMD) Increases By Infinity” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/25/short-interest-in-therapeuticsmd-inc-txmd-increases-by-infinity.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.